GlassScriptPhysician profile
Ramses Rojas
NPI 1194082859
$3,838.62
in general payments reported to CMS, 2019-2025
33 companies · $600 in 2025
The $600 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $418 · 2020: $510 · 2021: $532 · 2022: $627 · 2023: $590 · 2024: $561 · 2025: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,751.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,244.77 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $377.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $362.02 | 2019-2025 | Otezla, Evenity, Repatha |
| Pfizer INC. | $265.80 | 2019-2024 | |
| Abbvie INC. | $240.62 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $192.20 | 2019-2024 | Xarelto |
| Allergan, INC. | $133.58 | 2020 | |
| Lilly USA, LLC | $131.93 | 2019-2024 | Zepbound, Mounjaro, Jardiance |
| Boston Scientific Corporation | $101.75 | 2020-2024 | Watchman Flx |
| Amarin Pharma, INC. | $85.05 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $81.26 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.89 | 2024-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $64.75 | 2019-2023 | Vaxneuvance, Pneumovax 23 |
| Dexcom, INC. | $46.97 | 2021-2023 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $41.46 | 2020-2024 | Nexletol |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $35.32 | 2025 | Inspire |
| Axsome Therapeutics, INC. | $34.11 | 2024 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.92 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $29.32 | 2021-2022 | |
| Inogen, INC. | $28.05 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $26.53 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $23.81 | 2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $23.47 | 2021 | |
| Radius Health, INC. | $23.01 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.44 | 2022 | |
| Astellas Pharma US INC | $18.72 | 2019 | |
| Saluda Medical Americas, INC. | $17.93 | 2025 | Evoke |
| Abbott Laboratories | $17.77 | 2022 | |
| Ibsa Pharma INC. | $17.69 | 2020 | |
| Daiichi Sankyo INC. | $16.04 | 2021 | |
| Sanofi Pasteur INC. | $14.63 | 2023 | |
| Sunovion Pharmaceuticals INC. | $12.89 | 2020 | |
| Arbor Pharmaceuticals, INC. | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramses Rojas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.